Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge Setup Score
Trend Edge rates BBIO Bullish with a Setup Score of 80, net conviction 52, actionability 122. How the Setup Score works →
Total Setup Score
80
Directional Bias
Bullish
Net Conviction
52
Actionability
122 (in range)
Key signals behind this score
Fresh Trend Turn — 200wk turn 49w · aligned 14w
80wk Uptrend — rising+above (sma 61.84 vs px 65.35)
200wk Uptrend — rising+above (sma 39.98 vs px 65.35)
Funds Accumulating — momZ +0.93 · 5.10→5.32
Short Squeeze Setup — velZ +0.94 · age 8w×1.00 · 13.07%
Founder-Led — founder/CEO led
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cof… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: June 27, 2019
Headquarters: 3160 Porter Drive, Palo Alto, CA, United States, 94304
Founder-Led: Yes — Neil Kumar (Co-Founder, CEO & Director), Charles Homcy (Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director), Francis Patrick McCormick (Co-Founder, Chairman of Oncology & Director)
Key Metrics
Current Price
$65.35
Market Cap
$12.71B
Float
167.2M
Shares Outstanding
195.5M
Price/Sales (TTM)
17.83
vs. Analyst Target
+66.9% to analyst PT
Profit Margin
-97.03%
Operating Margin (TTM)
-43.94%
Revenue (TTM)
$713M
Dividend Rate
None
Analyst Target Price
$109.05 (22 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$8.2M
-$449M
$8.2M
-$467M
2021
$69.7M
-$563M
$66.6M
-$534M
2022
$77.6M
-$481M
$74.2M
-$397M
2023
$9.3M
-$643M
$6.9M
-$565M
2024
$222M
-$536M
$218M
-$437M
2025
$502M
-$729M
$474M
-$673M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
$121M
-$183M
Dec 2025
$154M
-$197M
Mar 2026
$195M
-$164M
Jun 2026
$222M
-$152M
Ownership & Float
Insider Ownership
3.9%
Institutional Ownership
99.6%
Short Float
13.1%
% of All Funds Holding
5.32%
Number of Funds Holding
468
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$73.45
Near-term / short-term trend
Weekly
40-Week SMA
$72.72
Medium-term trend
Weekly
80-Week SMA
$61.84
Cyclical trend (business cycle)
Weekly
200-Week SMA
$39.98
Secular trend (multi-year)
Monthly
10-Month SMA
$71.77
Near-term monthly trend
Monthly
20-Month SMA
$61.51
Medium-term monthly trend
Monthly
40-Month SMA
$45.53
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$76.00
resistance
1.02x
0 months ago
$65.00
support
1.44x
3 months ago
$47.00
support
1.08x
13 months ago
$34.60
support
1.21x
15 months ago
$33.90
support
1.33x
17 months ago
Historical Earnings Reactions (30 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
-0.09%
-0.03%
46.67%
6.01%
-9.57%
1 Day
-0.31%
0.16%
50.00%
12.12%
-14.33%
1 Week
0.53%
0.50%
53.33%
17.19%
-18.95%
2 Weeks
-1.10%
0.09%
50.00%
20.48%
-47.78%
1 Month
5.09%
3.02%
55.17%
38.72%
-23.19%
Next earnings: November 4, 2026 (24 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-4.3%
42.9%
7
Feb
1.0%
42.9%
7
Mar
7.8%
42.9%
7
Apr
-6.8%
28.6%
7
May
-3.8%
28.6%
7
Jun
14.5%
85.7%
7
Jul
12.6%
62.5%
8
Aug
2.9%
62.5%
8
Sep
-6.2%
25.0%
8
Oct
4.2%
71.4%
7
Nov
10.3%
71.4%
7
Dec
4.7%
71.4%
7
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.26%
49.6%
343
Tuesday
0.32%
50.5%
378
Wednesday
-0.00%
48.7%
374
Thursday
0.06%
48.9%
366
Friday
0.32%
48.9%
366
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 99.6%
Insider Transactions — Smart Summary
Total insider ownership: 3.9%
Founder-led management: Neil Kumar (Co-Founder, CEO & Director), Charles Homcy (Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director), Francis Patrick McCormick (Co-Founder, Chairman of Oncology & Director)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for BridgeBio Pharma Inc
(BBIO) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.